Beijing Beilu Pharmaceutical Shows Strong Financial Growth and Improved Valuation Metrics

Beijing Beilu Pharmaceutical Co., Ltd., a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an evaluation adjustment that reflects a shift in its valuation metrics. The company has demonstrated notable financial performance, particularly in its latest quarter ending March 2026, where it reported a significant growth in operating profit of 24.59%. This marks a continuation of positive results, as the company has achieved favorable outcomes for five consecutive quarters. Key financial indicators reveal a valuation that is now considered fair, with a P/E ratio of 54 and a price-to-book value of 1.83. The company’s operating cash flow reached its highest at CNY 255.83 million, while net sales for the half-year stood at CNY 652.96 million, reflecting a growth rate of 21.7%. Additionally, the return on capital employed (ROCE) has also seen an uptick, reaching 6.18%. The PEG ratio is notably low at 0.07, suggesting a favorable valuation relative to growth expectations. Overall, the adjustments in evaluation highlight the company's solid market position and performance indicators, reinforcing its standing in the industry. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.